Physician profile
Hugh H Sharp
NPI 1740282482
$3,624.73
in general payments reported to CMS, 2019-2025
15 companies · $869 in 2025
The $869 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $243 · 2021: $575 · 2022: $469 · 2023: $603 · 2024: $468 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,117.75 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $631.98 | 2021-2025 | Caplyta |
| Allergan, INC. | $361.40 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $320.07 | 2019-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $260.37 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $176.16 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $173.41 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $158.55 | 2023-2025 | Auvelity |
| Neos Therapeutics, LP | $116.41 | 2019-2023 | Adzenys Xr-Odt |
| Alkermes, INC. | $87.52 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $65.10 | 2019-2024 | Rexulti |
| Shire North American Group INC | $56.91 | 2019 | |
| Vanda Pharmaceuticals INC. | $34.72 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $33.83 | 2019 | |
| Supernus Pharmaceuticals, INC. | $30.55 | 2022-2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.